Predictive model improves growth hormone therapy outcomes for children with GHD

Growth hormone (GH) therapy significantly improves height outcomes in children with idiopathic growth hormone deficiency (GHD), and a newly developed predictive model accurately estimates individual growth responses during the first 2 years of treatment, according to a study.

The study included data from 669 prepubertal patients in the LG Growth Study (LGS) registry. Growth hormone therapy was found to significantly improve height outcomes, with the average height standard deviation score (SDS) increasing from -2.50 to -1.35 over 2 years. Growth velocity peaked at 9.06 cm during the first year before slowing to 7.42 cm in the second year. Key variables influencing outcomes included age, birth weight, bone age, initial height SDS, mid-parental height, GH dosage, and early treatment response. These factors explained 76.9% and 84.1% of the variability in height changes during the first and second years, respectively.

The findings highlight the potential of predictive models to optimize GH therapy, tailoring treatment to individual patient profiles.

Reference
Jeong HR, Lee HS, Hwang JS. Growth Prediction Model for Prepubertal Children With Idiopathic Growth Hormone Deficiency: An Analysis of LG Growth Study Data. Clin Endocrinol (Oxf). 2024;doi: 10.1111/cen.15178. Epub ahead of print. PMID: 39676465.